These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 16310074)

  • 41. Botulinum toxin type-A (BOTOX) in the treatment of occipital neuralgia: a pilot study.
    Taylor M; Silva S; Cottrell C
    Headache; 2008; 48(10):1476-81. PubMed ID: 19076646
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The therapeutic use of botulinum toxin in cervical and maxillofacial conditions: an evidence-based review.
    Ihde SK; Konstantinovic VS
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 Aug; 104(2):e1-11. PubMed ID: 17560141
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Safe botulinum toxin type A injection in patients with history of eyelid ptosis.
    Ghalamkarpour F; Aghazadeh Y; Odabaei G
    J Cosmet Dermatol; 2009 Jun; 8(2):98-102. PubMed ID: 19527332
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Novel cutaneous uses for botulinum toxin type A.
    Bansal C; Omlin KJ; Hayes CM; Rohrer TE
    J Cosmet Dermatol; 2006 Sep; 5(3):268-72. PubMed ID: 17177750
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Repeated botulinum toxin A injections for the treatment of lines in the upper face: a retrospective study of 4,103 treatments in 945 patients.
    Rzany B; Dill-Müller D; Grablowitz D; Heckmann M; Caird D;
    Dermatol Surg; 2007 Jan; 33(1 Spec No.):S18-25. PubMed ID: 17241409
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Botulinum toxin in facial rejuvenation: an update.
    Carruthers J; Carruthers A
    Obstet Gynecol Clin North Am; 2010 Dec; 37(4):571-82, ix. PubMed ID: 21093750
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Monitoring the safety of medicines used off-label.
    Dal Pan GJ
    Clin Pharmacol Ther; 2012 May; 91(5):787-95. PubMed ID: 22472983
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Reporting a side effect].
    Roos N; Vigan M
    Ann Dermatol Venereol; 2009 Oct; 136 Suppl 6():S381-5. PubMed ID: 19931702
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Generic patient self-report and investigator report instruments of therapeutic safety and tolerability.
    Lassere MN; Johnson KR; Van Santen S; Carlton K; Rappo J; Michael R; Kirwan JR; Edmonds JP
    J Rheumatol; 2005 Oct; 32(10):2033-6. PubMed ID: 16206365
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Signal detection of botulinum toxin type A (BoNT/A) using the Korea Adverse Event Reporting System Database, 1999 - 2016.
    Lee SE; Lee SH; Shin JY
    Int J Clin Pharmacol Ther; 2021 May; 59(5):386-397. PubMed ID: 33480840
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Serious and long-term adverse events associated with the therapeutic and cosmetic use of botulinum toxin.
    Yiannakopoulou E
    Pharmacology; 2015; 95(1-2):65-9. PubMed ID: 25613637
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Beauty and the beast.
    Kennedy D
    Science; 2002 Mar; 295(5560):1601. PubMed ID: 11872803
    [No Abstract]   [Full Text] [Related]  

  • 53. [Vigilance in esthetic dermatology].
    Vigan M
    Ann Dermatol Venereol; 2009 Oct; 136 Suppl 6():S375-80. PubMed ID: 19931701
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Botulinum toxin type A.
    Carruthers A; Carruthers J
    J Am Acad Dermatol; 2005 Aug; 53(2):284-90. PubMed ID: 16021124
    [No Abstract]   [Full Text] [Related]  

  • 55. Botulinum Toxin in the Field of Dermatology: Novel Indications.
    Kim YS; Hong ES; Kim HS
    Toxins (Basel); 2017 Dec; 9(12):. PubMed ID: 29258169
    [TBL] [Abstract][Full Text] [Related]  

  • 56. An innovative method of collecting adverse events data.
    Kellogg VA
    Outcomes Manag; 2003; 7(4):174-80. PubMed ID: 14618776
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Physicians' Practice of the Non-Cosmetic Uses of Botulinum Toxin: A Cross-Sectional Study in Saudi Arabia.
    Alzarah SA; Alabasi H; Alanazi L; Aldawsari M; Aldawsari E; Iqbal S
    Cureus; 2022 Jan; 14(1):e21326. PubMed ID: 35186585
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Epidemiologists and adverse event data--a challenge to the field.
    Bortnichak EA; Dai WS;
    Pharmacoepidemiol Drug Saf; 1999 Oct; 8(6):457-61. PubMed ID: 15073907
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Monitoring adverse drug events: need for an active surveillance system.
    Bavdekar SB
    Indian Pediatr; 2004 Aug; 41(8):860-1. PubMed ID: 15347881
    [No Abstract]   [Full Text] [Related]  

  • 60. Commentary: Reporting of adverse events is worth the effort.
    Ferner RE
    BMJ; 2000 Apr; 320(7243):1186-7. PubMed ID: 10836821
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.